Loading…

Ypsomed completed the sale of its pen needle and blood glucose monitoring businesses to Medical Technology and Devices (MTD). The deal was first announced in March 2024, and Ypsomed will transition production equipment to MTD by mid-2025.
“Ypsomed announced today that it completed the sale of its pen needle and blood glucose monitoring (BGM) businesses to Medical Technology and Devices (MTD).”drugdeliverybusiness.com
Summarized from public sources; check the original articles before acting on it.